{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:59:28Z","timestamp":1790510368609,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T00:00:00Z","timestamp":1662768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T00:00:00Z","timestamp":1662768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C14315\/A13462X"],"award-info":[{"award-number":["C14315\/A13462X"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C14315\/A13462X"],"award-info":[{"award-number":["C14315\/A13462X"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C14315\/A13462X"],"award-info":[{"award-number":["C14315\/A13462X"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,11,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We report copy-number profiling by low-pass WGS (LP-WGS) in individual circulating tumour cells (CTCs) for guiding treatment in patients with metastatic breast cancer (MBC), comparing CTC results with mutations detected in circulating tumour DNA (ctDNA) in the same blood samples.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Across 10 patients with MBC who were progressing at the time of blood sampling and that had &gt;20 CTCs detected by CellSearch<jats:sup>\u00ae<\/jats:sup>, 63 single cells (50 CTCs and 13 WBCs) and 16 cell pools (8 CTC pools and 8 WBC pools) were recovered from peripheral blood by CellSearch<jats:sup>\u00ae<\/jats:sup>\/DEPArray\u2122 and sequenced with Ampli1 LowPass technology (Menarini Silicon Biosystems). Copy-number aberrations were identified using the MSBiosuite software platform, and results were compared with mutations detected in matched plasma cfDNA analysed by targeted next-generation sequencing using the Oncomine\u2122 Breast cfDNA Assay (Thermo Fisher).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>LP-WGS data demonstrated copy-number gains\/losses in individual CTCs in regions including <jats:italic>FGFR1, JAK2<\/jats:italic> and <jats:italic>CDK6<\/jats:italic> in five patients, <jats:italic>ERBB2<\/jats:italic> amplification in two HER2-negative patients and <jats:italic>BRCA<\/jats:italic> loss in two patients. Seven of eight matched plasmas also had mutations in ctDNA in <jats:italic>PIK3CA, TP53, ESR1<\/jats:italic> and <jats:italic>KRAS<\/jats:italic> genes with mutant allele frequencies (MAF) ranging from 0.05 to 33.11%. Combining results from paired CTCs and ctDNA, clinically actionable targets were identified in all ten patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This combined analysis of CTCs and ctDNA may offer a new approach for monitoring of disease progression and to direct therapy in patients with advanced MBC, at a time when they are coming towards the end of other treatment options.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-022-01962-9","type":"journal-article","created":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T18:02:44Z","timestamp":1662832964000},"page":"1858-1864","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer"],"prefix":"10.1038","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4438-9666","authenticated-orcid":false,"given":"Daniel","family":"Fernandez-Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Nteliopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Hastings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Rushton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0440-9244","authenticated-orcid":false,"given":"Karen","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4887-8632","authenticated-orcid":false,"given":"Rebecca C.","family":"Allsopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bana","family":"Ambasager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Gleason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0418-580X","authenticated-orcid":false,"given":"David S.","family":"Guttery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1320-0816","authenticated-orcid":false,"given":"Simak","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4811-1100","authenticated-orcid":false,"given":"R.","family":"Charles Coombes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4227-503X","authenticated-orcid":false,"given":"Jacqueline A.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,10]]},"reference":[{"key":"1962_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2018;68:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"1962_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1146\/annurev-med-052209-100305","volume":"62","author":"S Ali","year":"2011","unstructured":"Ali S, Buluwela L, Coombes RC. Antiestrogens and their therapeutic applications in breast cancer and other diseases. Annu Rev Med. 2011;62:217\u201332.","journal-title":"Annu Rev Med"},{"key":"1962_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ccell.2017.01.002","volume":"31","author":"A Bardelli","year":"2017","unstructured":"Bardelli A, Pantel K. Liquid biopsies, what we do not know (yet). Cancer Cell. 2017;31:172\u20139.","journal-title":"Cancer Cell"},{"key":"1962_CR4","doi-asserted-by":"crossref","unstructured":"Rushton AJ, Nteliopoulos G, Shaw JA, Coombes RC. A review of circulating tumour cell enrichment technologies. Cancers. 2021;13:970.","DOI":"10.3390\/cancers13050970"},{"key":"1962_CR5","doi-asserted-by":"crossref","unstructured":"Rack B, Schindlbeck C, Juckstock J, Andergassen U, Hepp P, Zwingers T, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014;106:dju066.","DOI":"10.1093\/jnci\/dju066"},{"key":"1962_CR6","doi-asserted-by":"publisher","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","volume":"14","author":"JS de Bono","year":"2008","unstructured":"de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302\u20139.","journal-title":"Clin Cancer Res"},{"key":"1962_CR7","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1200\/JCO.2000.18.7.1432","volume":"18","author":"BM Smith","year":"2000","unstructured":"Smith BM, Slade MJ, English J, Graham H, Luchtenborg M, Sinnett HD, et al. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J Clin Oncol. 2000;18:1432\u20139.","journal-title":"J Clin Oncol"},{"key":"1962_CR8","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJMoa040766","volume":"351","author":"M Cristofanilli","year":"2004","unstructured":"Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl J Med. 2004;351:781\u201391.","journal-title":"N. Engl J Med"},{"key":"1962_CR9","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","volume":"376","author":"M Jamal-Hanjani","year":"2017","unstructured":"Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, et al. Tracking the evolution of non-small-cell lung cancer. N. Engl J Med. 2017;376:2109\u201321.","journal-title":"N. Engl J Med"},{"key":"1962_CR10","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"C Abbosh","year":"2017","unstructured":"Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446\u201351.","journal-title":"Nature"},{"key":"1962_CR11","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/ng.2823","volume":"45","author":"DR Robinson","year":"2013","unstructured":"Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45:1446\u201351.","journal-title":"Nat Genet"},{"key":"1962_CR12","doi-asserted-by":"publisher","first-page":"111ra121","DOI":"10.1126\/scitranslmed.3003161","volume":"3","author":"S Roychowdhury","year":"2011","unstructured":"Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011;3:111ra121.","journal-title":"Sci Transl Med"},{"key":"1962_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1158\/1078-0432.CCR-16-0825","volume":"23","author":"JA Shaw","year":"2017","unstructured":"Shaw JA, Guttery DS, Hills A, Fernandez-Garcia D, Page K, Rosales BM, et al. Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high circulating tumor cell counts. Clin Cancer Res. 2017;23:88\u201396.","journal-title":"Clin Cancer Res"},{"key":"1962_CR14","doi-asserted-by":"publisher","first-page":"6086","DOI":"10.1158\/1078-0432.CCR-17-1173","volume":"23","author":"C Paolillo","year":"2017","unstructured":"Paolillo C, Mu Z, Rossi G, Schiewer MJ, Nguyen T, Austin L, et al. Detection of activating estrogen receptor gene (ESR1) mutations in single circulating tumor cells. Clin Cancer Res. 2017;23:6086\u201393.","journal-title":"Clin Cancer Res"},{"key":"1962_CR15","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1158\/0008-5472.CAN-17-2686","volume":"78","author":"C Paoletti","year":"2018","unstructured":"Paoletti C, Cani AK, Larios JM, Hovelson DH, Aung K, Darga EP, et al. Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms. Cancer Res. 2018;78:1110\u201322.","journal-title":"Cancer Res"},{"key":"1962_CR16","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1002\/cyto.a.23687","volume":"93","author":"M Di Trapani","year":"2018","unstructured":"Di Trapani M, Manaresi N, Medoro G. DEPArray system: an automatic image-based sorter for isolation of pure circulating tumor cells. Cytom A. 2018;93:1260\u20136.","journal-title":"Cytom A"},{"key":"1962_CR17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nm.4239","volume":"23","author":"L Carter","year":"2017","unstructured":"Carter L, Rothwell DG, Mesquita B, Smowton C, Leong HS, Fernandez-Gutierrez F, et al. Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. Nat Med. 2017;23:114\u20139.","journal-title":"Nat Med"},{"key":"1962_CR18","doi-asserted-by":"publisher","first-page":"26107","DOI":"10.18632\/oncotarget.8431","volume":"7","author":"F De Luca","year":"2016","unstructured":"De Luca F, Rotunno G, Salvianti F, Galardi F, Pestrin M, Gabellini S, et al. Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer. Oncotarget. 2016;7:26107\u201319.","journal-title":"Oncotarget"},{"key":"1962_CR19","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/nm.3600","volume":"20","author":"CL Hodgkinson","year":"2014","unstructured":"Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, Trapani F, et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med. 2014;20:897\u2013903.","journal-title":"Nat Med"},{"key":"1962_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1235-8","volume":"21","author":"D Fernandez-Garcia","year":"2019","unstructured":"Fernandez-Garcia D, Hills A, Page K, Hastings RK, Toghill B, Goddard KS, et al. Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer. Breast Cancer Res. 2019;21:149.","journal-title":"Breast Cancer Res"},{"key":"1962_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"1962_CR22","doi-asserted-by":"publisher","first-page":"e0193689","DOI":"10.1371\/journal.pone.0193689","volume":"13","author":"A Ferrarini","year":"2018","unstructured":"Ferrarini A, Forcato C, Buson G, Tononi P, Del Monaco V, Terracciano M, et al. A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products. PLoS ONE. 2018;13:e0193689.","journal-title":"PLoS ONE"},{"key":"1962_CR23","unstructured":"R_Core_Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020."},{"key":"1962_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12:R41.","journal-title":"Genome Biol"},{"key":"1962_CR25","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41568-018-0060-1","volume":"18","author":"Z Sondka","year":"2018","unstructured":"Sondka Z, Bamford S, Cole CG, Ward SA, Dunham I, Forbes SA. The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat Rev Cancer. 2018;18:696\u2013705.","journal-title":"Nat Rev Cancer"},{"key":"1962_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-018-0531-8","volume":"10","author":"D Tamborero","year":"2018","unstructured":"Tamborero D, Rubio-Perez C, Deu-Pons J, Schroeder MP, Vivancos A, Rovira A, et al. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. Genome Med. 2018;10:25.","journal-title":"Genome Med"},{"key":"1962_CR27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29:24\u201326.","journal-title":"Nat Biotechnol"},{"key":"1962_CR28","doi-asserted-by":"publisher","first-page":"21083","DOI":"10.1073\/pnas.1320659110","volume":"110","author":"X Ni","year":"2013","unstructured":"Ni X, Zhuo M, Su Z, Duan J, Gao Y, Wang Z, et al. Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci USA. 2013;110:21083\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1962_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/annonc\/mdx483","volume":"29","author":"C Fribbens","year":"2018","unstructured":"Fribbens C, Garcia Murillas I, Beaney M, Hrebien S, O\u2019Leary B, Kilburn L, et al. Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. Ann Oncol. 2018;29:145\u201353.","journal-title":"Ann Oncol"},{"key":"1962_CR30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10549-019-05512-5","volume":"180","author":"T Shibayama","year":"2020","unstructured":"Shibayama T, Low SK, Ono M, Kobayashi T, Kobayashi K, Fukada I, et al. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer. Breast Cancer Res Treat. 2020;180:331\u201341.","journal-title":"Breast Cancer Res Treat"},{"key":"1962_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1184-2","volume":"21","author":"C Riebensahm","year":"2019","unstructured":"Riebensahm C, Joosse SA, Mohme M, Hanssen A, Matschke J, Goy Y, et al. Clonality of circulating tumor cells in breast cancer brain metastasis patients. Breast Cancer Res. 2019;21:101.","journal-title":"Breast Cancer Res"},{"key":"1962_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1229-6","volume":"21","author":"AA Davis","year":"2019","unstructured":"Davis AA, Zhang Q, Gerratana L, Shah AN, Zhan Y, Qiang W, et al. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer. Breast Cancer Res. 2019;21:137.","journal-title":"Breast Cancer Res"},{"key":"1962_CR33","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3892\/or.2020.7650","volume":"44","author":"L Zou","year":"2020","unstructured":"Zou L, Imani S, Maghsoudloo M, Shasaltaneh MD, Gao L, Zhou J, et al. Genomewide copy number analysis of circulating tumor cells in breast cancer patients with liver metastasis. Oncol Rep. 2020;44:1075\u201393.","journal-title":"Oncol Rep."},{"key":"1962_CR34","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1158\/1078-0432.CCR-18-3571","volume":"25","author":"Z Su","year":"2019","unstructured":"Su Z, Wang Z, Ni X, Duan J, Gao Y, Zhuo M, et al. Inferring the evolution and progression of small-cell lung cancer by single-cell sequencing of circulating tumor cells. Clin Cancer Res. 2019;25:5049\u201360.","journal-title":"Clin Cancer Res"},{"key":"1962_CR35","doi-asserted-by":"crossref","unstructured":"Magbanua MJM, Rugo HS, Wolf DM, Hauranieh L, Roy R, Pendyala P, et al. Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time (CALGB 40502 and CALGB 40503, Alliance). Clin Cancer Res. 2018;24:1486\u201399.","DOI":"10.1158\/1078-0432.CCR-17-2312"},{"key":"1962_CR36","doi-asserted-by":"crossref","unstructured":"Rossi T, Gallerani G, Angeli D, Cocchi C, Bandini E, Fici P, et al. Single-cell NGS-based analysis of copy number alterations reveals new insights in circulating tumor cells persistence in early-stage breast cancer. Cancers. 2020;12:2490.","DOI":"10.3390\/cancers12092490"},{"key":"1962_CR37","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41568-019-0180-2","volume":"19","author":"L Keller","year":"2019","unstructured":"Keller L, Pantel K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat Rev Cancer. 2019;19:553\u201367.","journal-title":"Nat Rev Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01962-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01962-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01962-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:04:45Z","timestamp":1667952285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01962-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,11,9]]}},"alternative-id":["1962"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-01962-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,10]]},"assertion":[{"value":"26 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was approved by the Imperial College Healthcare Tissue Bank (ICHTB) Ethics Committee (project reference number: 12\/WA\/0196). Blood sample collection was conducted in accordance with the Declaration of Helsinki. All patients gave written informed consent prior to participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}